IRIS
ALTAVILLA, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.399
EU - Europa 11.073
AS - Asia 5.104
SA - Sud America 1.726
Continente sconosciuto - Info sul continente non disponibili 298
AF - Africa 145
OC - Oceania 12
Totale 29.757
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.115
RU - Federazione Russa 5.177
SG - Singapore 2.194
BR - Brasile 1.514
CN - Cina 1.467
IE - Irlanda 1.302
SE - Svezia 1.242
IT - Italia 926
HK - Hong Kong 539
DE - Germania 509
UA - Ucraina 486
GB - Regno Unito 341
FR - Francia 319
FI - Finlandia 265
VN - Vietnam 250
PL - Polonia 198
IN - India 142
CA - Canada 113
BD - Bangladesh 101
BE - Belgio 65
TR - Turchia 62
MX - Messico 55
AR - Argentina 54
IQ - Iraq 47
EC - Ecuador 44
CO - Colombia 41
ZA - Sudafrica 41
ES - Italia 40
NL - Olanda 38
ID - Indonesia 37
AT - Austria 32
UZ - Uzbekistan 28
CZ - Repubblica Ceca 24
JP - Giappone 24
MA - Marocco 24
VE - Venezuela 24
IL - Israele 23
PK - Pakistan 18
AE - Emirati Arabi Uniti 17
JM - Giamaica 16
AZ - Azerbaigian 15
CR - Costa Rica 15
IR - Iran 15
NI - Nicaragua 15
SA - Arabia Saudita 15
AL - Albania 14
TT - Trinidad e Tobago 14
BO - Bolivia 13
SV - El Salvador 13
KE - Kenya 12
PH - Filippine 12
CL - Cile 11
LT - Lituania 11
TN - Tunisia 11
CH - Svizzera 10
CI - Costa d'Avorio 10
GT - Guatemala 10
JO - Giordania 10
NP - Nepal 10
PY - Paraguay 10
SC - Seychelles 10
AU - Australia 9
EG - Egitto 9
KG - Kirghizistan 9
DO - Repubblica Dominicana 8
GR - Grecia 8
HN - Honduras 8
KZ - Kazakistan 8
OM - Oman 8
PS - Palestinian Territory 8
RS - Serbia 8
NO - Norvegia 7
PE - Perù 7
RO - Romania 6
TH - Thailandia 6
UY - Uruguay 6
AM - Armenia 5
AO - Angola 5
BA - Bosnia-Erzegovina 5
BG - Bulgaria 5
GE - Georgia 5
LB - Libano 5
PA - Panama 5
BY - Bielorussia 4
CW - ???statistics.table.value.countryCode.CW??? 4
DK - Danimarca 4
DZ - Algeria 4
ET - Etiopia 4
KR - Corea 4
KW - Kuwait 4
LV - Lettonia 4
MY - Malesia 4
PR - Porto Rico 4
PT - Portogallo 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
BB - Barbados 3
EE - Estonia 3
HR - Croazia 3
HU - Ungheria 3
Totale 29.424
Salva come PNG Salva come JPEG
Città #
Ashburn 1.581
Moscow 1.476
Dublin 1.302
Singapore 1.175
Chandler 990
Jacksonville 943
Dallas 925
San Jose 713
Nyköping 691
Hong Kong 534
Beijing 493
Council Bluffs 381
The Dalles 295
Los Angeles 260
Dearborn 251
Ann Arbor 244
Princeton 219
Cambridge 200
Medford 199
Warsaw 189
Lauterbourg 183
New York 173
Messina 161
Des Moines 154
Boardman 134
Munich 121
São Paulo 119
Lancaster 110
Buffalo 95
Tianjin 82
Jinan 78
Santa Clara 78
Ho Chi Minh City 76
Woodbridge 67
Brussels 62
Orem 53
Shenyang 52
Guangzhou 51
Hanoi 51
Redondo Beach 51
Rio de Janeiro 51
Houston 50
Turku 50
Chicago 49
Wilmington 48
Phoenix 47
Columbus 45
San Mateo 45
Frankfurt am Main 43
Atlanta 39
Nanjing 37
Montreal 36
Rome 36
Belo Horizonte 35
Brooklyn 34
Catania 34
San Francisco 32
Milan 31
Hyderabad 29
Hebei 27
Seattle 27
Vienna 27
Brasília 26
Pune 26
Tashkent 26
Zhengzhou 26
London 25
Washington 25
Denver 23
Jakarta 23
Tokyo 23
Baghdad 21
Chennai 21
North Bergen 21
Curitiba 20
Haikou 20
Helsinki 20
Nanchang 20
Porto Alegre 20
Düsseldorf 19
Istanbul 19
Mumbai 19
Norwalk 19
Nuremberg 19
Quito 19
Shanghai 19
Stockholm 19
Johannesburg 18
Charlotte 17
Dong Ket 17
Ningbo 17
Salvador 17
Boston 16
Ankara 15
Bremen 15
Campinas 15
Hangzhou 15
Managua 15
Philadelphia 15
Ribeirão Preto 15
Totale 16.609
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 434
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 254
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. 249
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 247
Mechanical dispersion and cardiotoxicity in patients who underwent chemotherapy for breast cancer: an echocardiographic study 243
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 243
Analysis of multilayer strain and myocardial work in patients undergoing chemotherapy treatment: a 12 months follow-up 239
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 238
Analisi dello stato di metilazione del promoter di O6-methylguanine DNA methyltransferase (MGMT) e TMS1/ASC nei gliomi cerebrali diffusi di basso grado: possibili implicazioni cliniche e prognostiche. 231
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 230
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 229
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 228
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 224
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 218
Myocardial damage pattern in women with breast cancer who underwent chemotherapy: strain polar maps analysis 215
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 213
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 211
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 208
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 207
Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. 205
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 205
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 204
Liquid biopsy for lung cancer early detection 201
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 200
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 199
Applications of genomics in NSCLC 197
Cancer screening in HIV-infected patients: early diagnosis in a high-risk population 197
An acute-leukaemia-like picture due to breast carcinoma cells. 196
[Serum levels of copper and zinc in patients with lung cancer] 195
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 194
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 194
Left atrial function in patients undergoing chemotherapy: additional value of 2D longitudinal strain 194
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast. 192
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 192
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 191
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 191
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 191
Razionale e tecniche della chirurgia citoriduttiva e della chemioipertermia peritoneale. 186
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 185
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 185
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 185
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 184
The treatment of peritoneal carcinomatosis in elderly patients. 182
Psycho-Neuro-Endocrine-Immune System (PNEI) Involvement as Prognostic Marker in Breast Cancer Patients at 10 Years of Follow Up 181
Unusual relapse of hepatocellular carcinoma 181
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 179
A PHASE III RANDOMIZED TRIAL COMPARING THREE PLATINUM-BASED DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PS=2 VS 0 OR 1 AND AGE ³70 VS <70 ON CHEMOTHERAPY OUTCOME 178
A novel HPLC method for the determination of mitoxantrone in pharmaceutical formulations. 178
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 176
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 176
Espressione differenziale di un panel di miRNA in tumori cerebrali astrogliali con diverso grado di malignità. 176
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 175
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 175
Analytical profile and release of lonidamine from pharmaceutical formulation 174
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 174
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 172
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 171
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 170
Peritoneal carcinomatosis of colorectal origin. 167
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 167
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 166
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 163
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy 163
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 163
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 163
Targeted drugs in small-cell lung cancer 162
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 160
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 159
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 158
La farmacogenomica nei tumori del polmone 157
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 157
Gemcitabine combined with Oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma 157
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. 156
Thyroid function, autoimmunity and nodules in hematological malignancies 156
Sternal metastasis as initial presentation of a unknown rectal cancer 154
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 154
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 152
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 152
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 152
Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study 152
A PHASE II STUDY (21 day regimen) OF GEMCITABINE (Gem) AND CISPLATIN ( Cis) IN ADVANCED/METASTATIC TRANSITIONAL CELL CARCINOMA (TTC) OF BLADDER 150
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 150
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 149
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 147
Use of bisphosphonates in oncology 147
Transpersonal Therapy Combined with Best Supportive Care In Hospice Improve Patient’s Quality of Life and Quality Of Death 146
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). 146
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 145
How cells respond to interferons. 145
Studio anatomo-clinico di due casi di sarcoma sinoviale monofasico del ginocchio 144
Beyond global longitudinal strain: early impairment of apical function after antracyclines therapy 143
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 143
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 142
Temozolomide-induced shrinkage of a pituitary carcinoma. 142
Serum levels of copper and zinc in patients with lung cancer 137
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 137
Behavior of serum sialic acid levels at various stages of neoplastic disease 136
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 136
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 136
Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design 134
Totale 18.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.859
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.859
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.229 0 0 0 0 58 20 84 60 31 244 269 463
2022/20233.895 309 370 174 284 303 396 57 235 1.601 22 95 49
2023/2024988 73 128 66 114 73 258 23 45 3 79 26 100
2024/20254.298 57 38 74 252 221 134 75 1.015 1.146 250 337 699
2025/202612.011 617 662 1.003 691 969 2.672 1.495 1.488 1.493 476 221 224
2026/20272.105 218 535 563 695 94 0 0 0 0 0 0 0
Totale 29.757